Showing 91-100 of 333 grants
Title | Institution | Researcher | Program | Duration | Total Award Amount |
---|---|---|---|---|---|
Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494,000.00 |
Program to Achieve FDA Agreement on Design of Confirmatory Trial for Verapamil | Kinexum LLC | Michael Zemel | Cures | 01-December-2024 to 30-June-2025 | $160,000.00 |
Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200,000.00 |
Transcriptional memory in human islet organogenesis | Lundquist Institute for Biomedical Medical Innovation at Harbor‐UCLA Medical Center (The Lundquist Institute) | Eiji Yoshihara | Cures | 01-April-2022 to 31-March-2027 | $749,995.50 |
Demand for Combined CGM-Pump Devices in Type 1 Diabetes | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-August-2025 to 15-February-2026 | $291,000.00 |
T1D Adjunct Therapy Product & Patient Profiling Study | Magnolia Innovation, LLC | Kenneth Howie | Improving Lives | 01-December-2024 to 30-September-2025 | $434,000.00 |
The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O'Donnell | Improving Lives | 01-July-2023 to 30-June-2026 | $390,792.17 |
Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D | Massachusetts General Hospital | Mark Poznansky | Cures | 01-April-2023 to 31-March-2026 | $777,168.00 |
A Nanosensor Embedded Device for Rapid Insulin Measurement | Massachusetts Institute of Technology | Michael Strano | Improving Lives | 01-April-2024 to 31-March-2027 | $600,000.00 |
Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Patients | Mayo Clinic | Adrian Vella | Improving Lives | 01-October-2019 to 31-March-2025 | $437,405.39 |